Stocktoria
Divi's Laboratories Limited DIVISLAB.NS
Divi's Laboratories Limited statistics & valuation
Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value (₹1,172.36); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
P / E vs its own history
Divi's Laboratories Limited trades at about 87.6× earnings — above its 10-year norm (10-year range 47.6×–73.8×, median 67.2×).
Shaded band = 10-year range (47.6×–73.8×); dot = today's 87.6×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Gross margin | 59.1% | 58.5% | 58.1% | 58.5% |
| Operating margin | 28.4% | 27.6% | 23.5% | 26.4% |
| Net margin | 24.5% | 23.5% | 20.5% | 23.8% |
| FCF margin | 2.1% | 2.3% | 3.3% | 25.9% |
| Return on assets | 12.8% | 12.9% | 10.3% | 12.6% |
| Return on equity | 15.3% | 14.6% | 11.8% | 14.3% |
| Current ratio | 5.43 | 6.94 | 7.57 | 8.46 |
Computed from company filings · IN · as of 2026-03-31. Figures in INR. Facts plus Stocktoria's own computed scores — not investment advice.